Massimo Breccia | Ricerc@Sapienza

Pubblicazioni

Titolo	Pubblicato in	Anno
COVID-19 infection in chronic myeloid leukaemia after oneyear of the pandemic in Italy. A Campus CML report	BRITISH JOURNAL OF HAEMATOLOGY	2022
Circulating cell‐free DNA for target quantification in hematologic malignancies: Validation of a protocol to overcome pre‐analytical biases	HEMATOLOGICAL ONCOLOGY	2022
Future Management of Chronic Myeloid Leukemia: From Dose Optimization to New Agents	CURRENT CANCER DRUG TARGETS	2022
Reduced Klebsiella pneumoniae carbapenemase-producing K. pneumoniae (KPC-KP) colonization in a hematological-emergency setting during the coronavirus disease 2019 (COVID-19) pandemic	INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY	2022
CML Resistant to 2nd-Generation TKIs: Mechanisms, Next Steps, and New Directions	CURRENT HEMATOLOGIC MALIGNANCY REPORTS	2022
Novel therapeutic agents for myelofibrosis after failure or suboptimal response to JAK2 inhbitors	CURRENT OPINION IN ONCOLOGY	2022
Autologous stem cell transplantation in favorable-risk acute myeloid leukemia: single-center experience and current challenges	INTERNATIONAL JOURNAL OF HEMATOLOGY	2022
RR6 prognostic model provides information about survival for myelofibrosis treated with ruxolitinib: validation in a real-life cohort	BLOOD ADVANCES	2022
From bench to bedside: bridging the gaps in best practices for real-world chronic myeloid leukemia care	EXPERT REVIEW OF HEMATOLOGY	2022
Asciminib in chronic myeloid leukemia	DRUGS OF TODAY	2022
Utility of procalcitonin and C-reactive protein as predictors of Gram-negative bacteremia in febrile hematological outpatients	SUPPORTIVE CARE IN CANCER	2022
Sequential occurrence of chronic myeloproliferative and lymphoproliferative neoplasms: a collaborative retrospective study by pH-negative MPN latial group	LEUKEMIA & LYMPHOMA	2022
Adherence to ruxolitinib, an oral JAK1/2 inhibitor, in patients with myelofibrosis: interim analysis from an Italian, prospective cohort study (ROMEI)	LEUKEMIA & LYMPHOMA	2022
Deferasirox in the management of iron overload in patients with myelofibrosis treated with ruxolitinib: The multicentre retrospective RUX-IOL study	BRITISH JOURNAL OF HAEMATOLOGY	2022
Treatment-Free Remission in Chronic Myeloid Leukemia Patients Treated With Low-Dose TKIs: A Feasible Option Also in the Real-Life. A Campus CML Study	FRONTIERS IN ONCOLOGY	2022
Physicians' Perceptions of Clinical Utility of a Digital Health Tool for Electronic Patient-Reported Outcome Monitoring in Real-Life Hematology Practice. Evidence From the GIMEMA-ALLIANCE Platform	FRONTIERS IN ONCOLOGY	2022
Safety and effectiveness of ruxolitinib in the real-world management of polycythemia vera patients: a collaborative retrospective study by pH-negative MPN latial group	ANNALS OF HEMATOLOGY	2022
Peripheral blasts are associated with responses to ruxolitinib and outcomes in patients with chronic-phase myelofibrosis	CANCER	2022
Acute promyelocytic leukaemia long-term survivors: higher fatigue and greater overall symptom burden	BMJ SUPPORTIVE & PALLIATIVE CARE	2022
Dihydroorotate dehydrogenase inhibition reveals metabolic vulnerability in chronic myeloid leukemia	CELL DEATH & DISEASE	2022